Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCLINYSE:CHRONASDAQ:GMDAQNASDAQ:TSBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCLIBrainstorm Cell Therapeutics$1.24+12.7%$1.10$0.72▼$6.94$9.84M0.24373,103 shs781,204 shsCHROChromocell Therapeutics$1.22-0.5%$1.20$0.45▼$3.80$8.05M3.22437,892 shs16,141 shsGMDAQGamida Cell$0.02$0.02$0.01▼$2.51$2.62M1.36.58 million shs332,754 shsTSBXTurnstone Biologics$0.35+4.1%$0.34$0.29▼$3.05$8.06M1.18256,117 shs64,067 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCLIBrainstorm Cell Therapeutics0.00%-9.84%-16.67%-30.38%-84.40%CHROChromocell Therapeutics0.00%+9.46%+22.60%-27.02%-5.69%GMDAQGamida Cell0.00%0.00%0.00%0.00%0.00%TSBXTurnstone Biologics0.00%-4.99%+2.33%-12.94%-87.30%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBCLIBrainstorm Cell Therapeutics4.0775 of 5 stars3.52.00.04.73.10.80.6CHROChromocell Therapeutics1.1726 of 5 stars0.04.00.00.02.82.50.0GMDAQGamida CellN/AN/AN/AN/AN/AN/AN/AN/ATSBXTurnstone Biologics3.3302 of 5 stars2.85.00.00.03.02.51.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCLIBrainstorm Cell Therapeutics 3.00Buy$30.002,319.35% UpsideCHROChromocell Therapeutics 3.00BuyN/AN/AGMDAQGamida Cell 0.00N/AN/AN/ATSBXTurnstone Biologics 1.50Reduce$0.4529.24% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/A($1.20) per shareN/ACHROChromocell TherapeuticsN/AN/AN/AN/A($1.65) per shareN/AGMDAQGamida Cell$1.78M1.47N/AN/A($0.02) per share-0.85TSBXTurnstone Biologics$19.31M0.42N/AN/A$4.27 per share0.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCLIBrainstorm Cell Therapeutics-$17.19M-$3.36N/AN/AN/AN/AN/A-528.56%8/13/2025 (Estimated)CHROChromocell Therapeutics-$7.38M-$1.24N/A∞N/AN/AN/A-453.90%N/AGMDAQGamida Cell-$63M-$0.49N/A∞N/AN/AN/A-60.18%N/ATSBXTurnstone Biologics-$55.20M-$2.73N/AN/AN/AN/A-105.99%-87.27%8/13/2025 (Estimated)Latest GMDAQ, BCLI, CHRO, and TSBX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025BCLIBrainstorm Cell Therapeutics-$0.38-$0.45-$0.07-$0.45N/AN/A5/8/2025Q1 2025TSBXTurnstone Biologics-$0.26-$0.51-$0.25-$0.51N/AN/A3/28/2025Q4 2024TSBXTurnstone Biologics-$0.69-$0.56+$0.13-$0.56N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCLIBrainstorm Cell TherapeuticsN/AN/AN/AN/AN/ACHROChromocell TherapeuticsN/AN/AN/AN/AN/AGMDAQGamida CellN/AN/AN/AN/AN/ATSBXTurnstone BiologicsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCLIBrainstorm Cell TherapeuticsN/A0.050.05CHROChromocell TherapeuticsN/A0.600.60GMDAQGamida CellN/A0.350.33TSBXTurnstone BiologicsN/A3.753.75Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCLIBrainstorm Cell Therapeutics14.33%CHROChromocell Therapeutics77.96%GMDAQGamida Cell50.34%TSBXTurnstone Biologics52.51%Insider OwnershipCompanyInsider OwnershipBCLIBrainstorm Cell Therapeutics11.15%CHROChromocell Therapeutics16.40%GMDAQGamida Cell6.72%TSBXTurnstone Biologics32.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCLIBrainstorm Cell Therapeutics407.94 million5.32 millionOptionableCHROChromocell Therapeutics46.60 million5.04 millionN/AGMDAQGamida CellN/A154.05 million143.70 millionOptionableTSBXTurnstone Biologics8223.14 million15.70 millionNot OptionableGMDAQ, BCLI, CHRO, and TSBX HeadlinesRecent News About These CompaniesTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent ...May 8, 2025 | gurufocus.comTurnstone Biologics Corp. Reports First Quarter 2025 Financial Results and Provides Recent Corporate HighlightsMay 8, 2025 | globenewswire.comTurnstone Biologics reports Q4 EPS (56c) vs (73c) last yearMarch 31, 2025 | markets.businessinsider.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | investing.comTurnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial ResultsMarch 28, 2025 | globenewswire.comTurnstone Biologics stock plunges to 52-week low of $0.4February 11, 2025 | msn.comTurnstone Biologics Corp. (TSBX) Upgraded to Buy: What Does It Mean for the Stock?February 7, 2025 | zacks.comTurnstone Biologics to explore strategic alternativesFebruary 6, 2025 | thepharmaletter.comTurnstone ends last remaining clinical program due to costs, plots more layoffsFebruary 5, 2025 | fiercebiotech.comTurnstone Biologics halts TIDAL-01 development, seeks alternativesFebruary 5, 2025 | msn.comTurnstone Biologics downgraded to Neutral from Overweight at Piper SandlerFebruary 5, 2025 | markets.businessinsider.comTurnstone Biologics Corp (TSBX) Stock: A Deeper Look at Its True PotentialFebruary 5, 2025 | bovnews.comTurnstone Biologics Corp. Discontinues TIDAL-01 Clinical Studies and Initiates Strategic Alternatives ReviewFebruary 4, 2025 | quiverquant.comTurnstone Biologics Announces Plans to Explore Strategic AlternativesFebruary 4, 2025 | finance.yahoo.comBofA downgrades Turnstone to Underperform on unfavorable marketNovember 16, 2024 | markets.businessinsider.comTurnstone Biologics downgraded to Underperform from Neutral at BofANovember 16, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Turnstone Biologics Corp. (TSBX)November 15, 2024 | markets.businessinsider.comTurnstone Biologics Faces Financial and Operational ChallengesNovember 14, 2024 | markets.businessinsider.comTurnstone Biologics Corp. Reports Third Quarter 2024 Financial Results and Provides Recent Business HighlightsNovember 12, 2024 | markets.businessinsider.comWhat’s Behind the 18.75% Gain in Turnstone Biologics Corp (TSBX) Stock? Find Out Now!November 7, 2024 | bovnews.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeGMDAQ, BCLI, CHRO, and TSBX Company DescriptionsBrainstorm Cell Therapeutics NASDAQ:BCLI$1.24 +0.14 (+12.73%) Closing price 04:00 PM EasternExtended Trading$1.25 +0.01 (+1.21%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Brainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; Phase II clinical trial for the treatment of progressive multiple sclerosis; and for the treatment of alzheimer's disease, as well as for other neurodegenerative diseases. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.Chromocell Therapeutics NYSE:CHRO$1.22 -0.01 (-0.53%) Closing price 04:00 PM EasternExtended Trading$1.26 +0.04 (+3.36%) As of 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the development and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain and acute and chronic eye pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey.Gamida Cell NASDAQ:GMDAQGamida Cell Ltd. is a biopharmaceutical company. It focuses on developing cell therapies to cure cancer and rare and serious hematologic diseases. The company's product pipeline consists of NiCord and NAM-NK which are in clinical stage. It operates primarily in the United States, the European Union and internationally. Gamida Cell Ltd. is headquartered in Jerusalem, Israel.Turnstone Biologics NASDAQ:TSBX$0.35 +0.01 (+4.10%) Closing price 04:00 PM EasternExtended Trading$0.35 +0.00 (+0.52%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New Catalysts to Drive NVIDIA’s Stock Price Even Higher Palantir Defies Bears, Leads S&P 500 in 2025 AST SpaceMobile’s Star Is Rising: Get in While It’s Still Cheap! Could Meta and Eli Lilly Trigger the Next Stock Split Boom? Iran Conflict Fuels Fertilizer Stocks’ Bullish Setup Is D-Wave's Latest $400M Sales Agreement a Dilution Deal-Breaker? Why Analysts Are Bullish on Celsius Stock After 30% Drop 3 Stocks With Rising Dividends Investors Shouldn’t Ignore Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
